How PKC gamma mutations cause cerebellar ataxia (SCA14)

Structural and Molecular Mechanisms for Dysregulation of Protein Kinase C Gamma in Cerebellar Ataxia

NIH-funded research University of California, San Diego · NIH-11297231

Researchers are working to understand how inherited changes in the brain protein PKC gamma lead to spinocerebellar ataxia type 14 so future treatments can be developed for people with that condition.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of California, San Diego NIH-funded
Lab location1 site (La Jolla, United States)
Project IDNIH-11297231 on NIH RePORTER

What this research studies

This project aims to find out how inherited mutations in PKC gamma damage cerebellar Purkinje cells and cause the balance and coordination problems of SCA14. The team will use structural biology to see how the protein's shape is changed, biochemical and live-cell imaging to measure abnormal activity, and proteomics to map altered protein interactions. They will also use animal models to observe how these molecular changes lead to neuron degeneration and movement problems. Together these approaches will test whether disease comes from inappropriate enzyme activity or from harmful new protein interactions, which will guide therapeutic ideas.

Who could benefit from this research

Good fit: People with genetically confirmed SCA14 (PKC gamma mutations) or families affected by SCA14 would be most directly connected to this research and may be invited to provide samples or join future clinical efforts.

Not a fit: People with other types of ataxia not caused by PKC gamma mutations, or individuals without a PKC gamma mutation, are unlikely to receive direct benefit from this project in the near term.

Why it matters

Potential benefit: If successful, the work could identify targets or strategies for drugs that slow or prevent Purkinje cell loss in SCA14.

How similar studies have performed: Previous laboratory studies, including work from this team, have shown SCA14 mutations change PKC gamma's conformation and increase its basal activity, but turning those findings into treatments remains early and experimental.

Where this research is happening

La Jolla, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.